Stock 1061 ESSEX BIO-TECHNOLOGY LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

All News Essex Bio-Technology Limited

Equities

1061

KYG312371035

Delayed Hong Kong S.E.
Other stock markets
 10:38:04 16/05/2024 am IST 		5-day change 1st Jan Change
2.58 HKD +2.79% Intraday chart for Essex Bio-Technology Limited +8.82% +4.02%
18/03 Essex Bio-Technology Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
03/01 Essex Bio-Technology Limited Announces Change of Address of Head Office And principal Place of Business in Hong Kong CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Essex Bio-Technology's 2023 Profit Jumps 22% on Higher Turnover
MT
Essex Bio-Technology Posts Sound 2023 Annual Financial Results, Revenue Up 29.5%, Profit Up 22.1%
AQ
Essex Bio-Technology Limited Proposes Final Ordinary Dividend for the Financial Year Ended 31 December 2023, Payable June 17, 2024
CI
Essex Bio-Technology Limited Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Essex Bio-Technology Limited Announces Change of Address of Head Office And principal Place of Business in Hong Kong
CI
Essex Bio-Technology Limited(SEHK:1061) dropped from S&P Global BMI Index
CI
Essex Bio-Technology's Profit Jumps 22% in H1
MT
Essex Bio-Technology Posts Sound 2023 Interim Financial Results, Revenue Up 37.1%, Profit Up 22%
AQ
Essex Bio-Technology Limited Declares Interim Dividend for the Six Months Ended June 30, 2023, Payable on September 13, 2023
CI
Essex Bio-Technology Limited Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Essex Bio-Technology's Ophthalmic Injection Showed Safety, Efficacy in Trial
MT
The phase 1/2 clinical trial of Bevacizumab for treatment of Ophthalmic Diseases completed
AQ
Essex Bio-Technology Limited Provides Update on the Phase 1/2 Clinical Study in Relation to the Co-Development of the Licensed Product with Henlius for the Treatment of Exudative Age-Related Macular Degeneration
CI
Essex Bio-Technology Limited Announces Early Repayment of Loan Facility
CI
Essex Bio-Technology Limited commences an Equity Buyback Plan for 57,064,900 shares, representing 10% of its issued share capital, under the authorization approved on June 9, 2023.
CI
Essex Bio-Technology Limited Announces Director Changes
CI
Essex Bio-Technology Limited Declares Final Dividend for the Year Ended 31 December 2022
CI
Essex Bio-Technology Limited's Equity Buyback announced on May 12, 2022 has expired.
CI
Essex and Osteopore Entered into Exclusive Distribution Agreement
AQ
Essex and Osteopore Entered into Exclusive Distribution Agreement for Oral Maxillofacial products in Singapore
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 1061 Stock
  4. News Essex Bio-Technology Limited
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW